Case number 1:24-cv-01084
Astellas Pharma Inc. et al v. Ascent Pharmaceuticals, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 14, 2025 | N/A | Pro Hac Vice Attorney Ashley Ross, Bryan S. Hales for Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., and Astellas Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 20-1589, 24-939, 24-940, 24-1068, 24-1069, 24-1084-JFB-EGT(cdd) (Entered: 04/14/2025) (0) |
| Apr 11, 2025 | N/A | Pro Hac Vice Attorney Jeanna M. Wacker for Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., and Astellas Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-cv-01589-JFB-EGT, 24-939, 24-940, 24-1068, 24-1069, & 24-1084.(cdd) (Entered: 04/11/2025) (0) |
| Feb 14, 2025 | 40 | ORAL ORDER - Plaintiffs' Motion to Seal and to Redact Portions of the January 16, 2025 Discovery Dispute Transcript (D.I. 669 in 20-1589-JFB-EGT, D.I. 141 in 23-486-JFB-EGT, D.I. 70 in 23-689-JFB-EGT, D.I. 420 in 23-819-JFB-EGT, D.I. 31 in 24-939-JFB-EGT, D.I. 30 in 24-940-JFB-EGT, D.I. 27 in 24-1068-JFB-EGT, D.I. 29 in 24-1069-JFB-EGT, D.I. 31 in 24-1084-JFB-EGT) is DENIED. The teleconference was open to the public and Plaintiffs did not request that the teleconference be sealed at any point. Plaintiffs also did not inquire as to whether any members of the public were on the line before stating that which they now seek to keep confidential. The Court is also not persuaded that the information sought to be redacted would work a clearly defined and serious competitive injury to Plaintiffs. See In re Avandia Marketing, Sales Practices & Products Liability Litigation, 924 F.3d 662, 672-73 (3d Cir. 2019). Indeed, Plaintiffs have not even attempted to make the requisite showing of harm with specificity, instead relying on broad and generic allegations of harm. More is needed to overcome the right of public access to judicial proceedings and records. ORDERED by Judge Eleanor G. Tennyson on 2/14/2025. Associated Cases: 1:20-cv-01589-JFB-EGT et al. (lah) (Entered: 02/14/2025) (0) |
| Feb 5, 2025 | N/A | Case associated to lead case 23-486. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE ONLY. (lah) (Entered: 02/05/2025) (0) |
| Feb 4, 2025 | 39 | PROPOSED ORDER Supplemental Scheduling by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Silver, Daniel) (Entered: 02/04/2025) (15) |
| Jan 31, 2025 | 38 | ORAL ORDER - Plaintiffs have informed the Court that their Delaware counsel and "primary expert witness" may have some unavailability during the trial dates provided by the Court at the scheduling conference (i.e., November 3-7, 2025). (See, e.g., D.I. 148 in 23-486-JFB-EGT). IT IS HEREBY ORDERED that Plaintiffs shall decide whether (1) they will proceed with the previously provided dates and with their expert testifying out of order or (2) whether Plaintiffs will proceed with a bench trial beginning October 27, 2025. IT IS FURTHER ORDERED that the parties' stipulation to extend time (D.I. 687 in 20-1589-JFB-EGT, D.I. 146 in 23-486-JFB-EGT, D.I. 72 in 23-689-JFB-EGT, D.I. 35 in 24-1084-JFB-EGT) is GRANTED with MODIFICATION. On or before February 4, 2025, the parties shall submit the revised proposed scheduling order consistent with Plaintiffs' election and without disputes or arguments in footnotes. ORDERED by Judge Eleanor G. Tennyson on 1/31/2025. Associated Cases: 20-1589-JFB-EGT, 23-486-JFB-EGT, 23-689-JFB-EGT, 24-1084-JFB-EGT (lah) (Entered: 01/31/2025) (0) |
| Jan 31, 2025 | 37 | Letter to The Honorable Eleanor G. Tennyson from Daniel M. Silver, Esq. regarding trial date for MSN and Ascent litigations. (Silver, Daniel) (Entered: 01/31/2025) (1) |
| Jan 30, 2025 | 36 | REDACTED VERSION of (420 in 1:23-cv-00819-JFB-EGT, 141 in 1:23-cv-00486-JFB-EGT, 31 in 1:24-cv-01084-JFB-EGT, 31 in 1:24-cv-00939-JFB-EGT, 29 in 1:24-cv-01069-JFB-EGT, 30 in 1:24-cv-00940-JFB-EGT, 669 in 1:20-cv-01589-JFB-EGT, 27 in 1:24-cv-01068-JFB-EGT, 70 in 1:23-cv-00689-JFB-EGT) Unopposed MOTION to Redact (29 in 1:24-cv-01084-JFB-EGT) Transcript,, (27 in 1:24-cv-01069-JFB-EGT) Transcript,, (25 in 1:24-cv-01068-JFB-EGT) Transcript,, (665 in 1:20-cv-01589-JFB-EGT) Transcript,, (28 in 1:24-cv-00940-JFB-EGT) Transcript,, (41 by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Joyce, Alexandra) (Entered: 01/30/2025) (30) |
| Jan 30, 2025 | 35 | STIPULATION TO EXTEND TIME the deadline for the parties to submit revised case schedules to February 6, 2025 - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Joyce, Alexandra) (Entered: 01/30/2025) (3) |
| Jan 27, 2025 | N/A | SO ORDERED, re (D.I. 33 in 1:24-cv-01084-JFB-EGT, D.I. 143 in 1:23-cv-00486-JFB-EGT) MOTION for Pro Hac Vice Appearance of Attorney Saukshmya Trichi, filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. ORDERED by Judge Eleanor G. Tennyson on 1/27/2025. Associated Cases: 1:23-cv-00486-JFB-EGT, 1:24-cv-01084-JFB-EGT (lah) (Entered: 01/27/2025) (0) |
| Jan 27, 2025 | 34 | Pro Hac Vice Fee - Credit Card Payment received for Saukshmya Trichi. ( re 33 MOTION for Pro Hac Vice Appearance of Attorney Saukshmya Trichi )( Payment of $ 50, receipt number ADEDC-4600407).(Dorsney, Kenneth) (Entered: 01/27/2025) (0) |
| Jan 27, 2025 | 33 | MOTION for Pro Hac Vice Appearance of Attorney Saukshmya Trichi - filed by MSN Pharmaceuticals Inc., MSN Laboratories Private Limited. Motions referred to Eleanor G. Tennyson.(Dorsney, Kenneth) (Entered: 01/27/2025) (3) |
| Jan 24, 2025 | N/A | SO ORDERED, re (D.I. 71 in 1:23-cv-00689-JFB-EGT, D.I. 142 in 1:23-cv-00486-JFB-EGT, D.I. 672 in 1:20-cv-01589-JFB-EGT, D.I. 32 in 1:24-cv-01084-JFB-EGT) STIPULATION and Proposed Order to Extend Time. Revised Proposed Scheduling Orders due by January 30, 2025. Signed by Judge Eleanor G. Tennyson on 1/24/2025. Associated Cases: 1:20-cv-01589-JFB-EGT, 1:23-cv-00486-JFB-EGT, 1:23-cv-00689-JFB-EGT, 1:24-cv-01084-JFB-EGT (lah) (Entered: 01/24/2025) (0) |
| Jan 24, 2025 | 32 | STIPULATION TO EXTEND TIME the deadline for the parties to submit revised case schedules to January 30, 2025 - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Joyce, Alexandra) (Entered: 01/24/2025) (3) |
| Jan 23, 2025 | 31 | [SEALED] Unopposed MOTION to Redact (29 in 1:24-cv-01084-JFB-EGT) Transcript,, (27 in 1:24-cv-01069-JFB-EGT) Transcript,, (25 in 1:24-cv-01068-JFB-EGT) Transcript,, (665 in 1:20-cv-01589-JFB-EGT) Transcript,, (28 in 1:24-cv-00940-JFB-EGT) Transcript,, (418 in 1:23-cv-00819-JFB-EGT) Transcript,, (68 in 1:23-cv-00689-JFB-EGT) Transcript,, (29 in 1:24-cv-00939-JFB-EGT) Transcript,, (139 in 1:23-cv-00486-JFB-EGT) Transcript,, - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Text of Proposed Order, # 4 Certificate of Service)Motions referred to Eleanor G. Tennyson.(Silver, Daniel) (Entered: 01/23/2025) (0) |
| Jan 23, 2025 | 30 | NOTICE of Intent to Request Redaction by Daniel M. Silver re (29 in 1:24-cv-01084-JFB-EGT) Transcript,, (27 in 1:24-cv-01069-JFB-EGT) Transcript,, (25 in 1:24-cv-01068-JFB-EGT) Transcript,, (665 in 1:20-cv-01589-JFB-EGT) Transcript,, (28 in 1:24-cv-00940-JFB-EGT) Transcript,, (418 in 1:23-cv-00819-JFB-EGT) Transcript,, (68 in 1:23-cv-00689-JFB-EGT) Transcript,, (29 in 1:24-cv-00939-JFB-EGT) Transcript,, (139 in 1:23-cv-00486-JFB-EGT) Transcript,, (Silver, Daniel) (Entered: 01/23/2025) (4) |
| Jan 23, 2025 | 29 | Official Transcript of Teleconference held on 01/16//25 before Judge Eleanor G. Tennyson. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/13/2025. Redacted Transcript Deadline set for 2/24/2025. Release of Transcript Restriction set for 4/23/2025. (Triozzi, Heather) (Entered: 01/23/2025) (45) |
| Jan 23, 2025 | N/A | SO ORDERED, re (D.I. 138 in 1:23-cv-00486-JFB-EGT, D.I. 67 in 1:23-cv-00689-JFB-EGT, D.I. 28 in 1:24-cv-01084-JFB-EGT, D.I. 663 in 1:20-cv-01589-JFB-EGT) STIPULATION and Proposed Order to Extend Time. Revised Proposed Scheduling Orders due by January 24, 2025. Signed by Judge Eleanor G. Tennyson on 1/23/2025. Associated Cases: 1:20-cv-01589-JFB-EGT, 1:23-cv-00486-JFB-EGT, 1:23-cv-00689-JFB-EGT, 1:24-cv-01084-JFB-EGT(lah) (Entered: 01/23/2025) (0) |
| Jan 22, 2025 | 28 | STIPULATION TO EXTEND TIME the deadline for the parties to submit revised case schedules to January 24, 2025 - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Silver, Daniel) (Entered: 01/22/2025) (3) |
| Jan 16, 2025 | N/A | Minute Entry for proceedings held before Judge Eleanor G. Tennyson - Telephonic Scheduling Conference held on 1/16/2025. The Court ordered the parties to submit a proposed scheduling order consistent with the dates provided at the conference by 1/22/2025. The parties are to use Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Magistrate Judge Tennyson, Forms). (Court Reporter Heather Triozzi.) Associated Cases: 1:20-cv-01589-JFB-EGT et al. (lah) (Entered: 01/16/2025) (0) |
| Jan 13, 2025 | 27 | ORAL ORDER - IT IS HEREBY ORDERED that a Telephonic Scheduling Conference is set for 1/16/2025 at 11:00 AM before Judge Eleanor G. Tennyson. Counsel shall provide a dial-in number for the teleconference by emailing egt_civil@ded.uscourts.gov. ORDERED by Judge Eleanor G. Tennyson on 1/13/2025. Associated Cases: 1:20-cv-01589-JFB-EGT et al. (lah) (Entered: 01/13/2025) (0) |
| Jan 13, 2025 | 26 | NOTICE OF SERVICE of Defendants MSN Laboratories Private Ltd. and MSN Pharmaceuticals Inc.'s 26(a)(1) Initial Disclosures filed by MSN Pharmaceuticals Inc., MSN Laboratories Private Limited.(Dorsney, Kenneth) (Entered: 01/13/2025) (3) |
| Jan 7, 2025 | 25 | Letter to The Honorable Joseph F. Bataillon and The Honorable Eleanor G. Tennyson from Daniel M. Silver, Esq. - re (652 in 1:20-cv-01589-JFB-EGT) Order,,,,. (Attachments: # 1 Attachment A)(Silver, Daniel) (Entered: 01/07/2025) (0) |
| Jan 6, 2025 | 24 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Charts filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc..(Silver, Daniel) (Entered: 01/06/2025) (3) |
| Dec 20, 2024 | 23 | NOTICE OF SERVICE of (1) Plaintiffs' First Amended Rule 26(A)(1) Initial Disclosures for Litigation Involving U.S. Patent Nos. 10,842,780, 12,059,409, 11,707,451, and 12,097,189 and (2) Plaintiffs' First Amended Initial Disclosures Identifying Defendant's Accused Products and Plaintiffs' Asserted Patents filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc..(Silver, Daniel) (Entered: 12/20/2024) (3) |
| Dec 18, 2024 | N/A | Pro Hac Vice Attorney Michael DelRossi for Astellas Ireland Co., Ltd.,Michael DelRossi for Astellas Pharma Global Development, Inc.,Michael DelRossi for Astellas Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (scs) (Entered: 12/18/2024) (0) |
| Dec 16, 2024 | 22 | ORAL ORDER - IT IS HEREBY ORDERED that, within twenty-one (21) days from the date of this Order, the parties shall meet and confer and submit a proposed scheduling order that is consistent with the guidance set forth in the Memorandum Order issued today in the related case Astellas Pharma Inc. et al. v. Sandoz Inc. et al., C.A. No. 20-1589-JFB (D.I. 652) and which includes a proposal for the length and timing of trial. In connection with this submission, the parties shall also provide their positions on coordination of these cases with currently pending actions involving Ascent Pharmaceuticals and MSN Pharmaceuticals (e.g., C.A. No. 24-1084-JFB-EGT). The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Magistrate Judge Tennyson, Forms). If there are deviations from the form order or disputes that the Court needs to address, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter accompanying the proposed schedule. ORDERED by Judge Eleanor G. Tennyson on 12/16/2024. Associated Cases: 1:24-cv-00939-JFB-EGT, 1:24-cv-00940-JFB-EGT, 1:24-cv-01068-JFB-EGT, 1:24-cv-01069-JFB-EGT, 1:24-cv-01084-JFB-EGT (lah) (Entered: 12/16/2024) (0) |
| Dec 5, 2024 | N/A | SO ORDERED, re (D.I. 13 in 1:24-cv-01069-JFB-EGT, D.I. 13 in 1:24-cv-01068-JFB-EGT, D.I. 18 in 1:24-cv-00940-JFB-EGT, D.I. 20 in 1:24-cv-01084-JFB-EGT, D.I. 22 in 1:24-cv-00939-JFB-EGT) MOTION for Pro Hac Vice Appearance of Attorney Michael DelRossi, filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc. ORDERED by Judge Eleanor G. Tennyson on 12/5/2024. Associated Cases: 1:24-cv-00939-JFB-EGT, 1:24-cv-00940-JFB-EGT, 1:24-cv-01068-JFB-EGT, 1:24-cv-01069-JFB-EGT, 1:24-cv-01084-JFB-EGT (lah) (Entered: 12/05/2024) (0) |
| Dec 4, 2024 | 21 | Pro Hac Vice Fee - Credit Card Payment received for Michael DelRossi. ( re 20 MOTION for Pro Hac Vice Appearance of Attorney Michael DelRossi )( Payment of $ 50, receipt number ADEDC-4562595).(Silver, Daniel) (Entered: 12/04/2024) (0) |
| Dec 4, 2024 | 20 | MOTION for Pro Hac Vice Appearance of Attorney Michael DelRossi - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Attachments: # 1 Certification for Michael DelRossi)Motions referred to Eleanor G. Tennyson.(Silver, Daniel) (Entered: 12/04/2024) (0) |
| Nov 20, 2024 | 19 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Ascent Pharmaceuticals, Inc.. (Hitch, Cortlan) (Entered: 11/20/2024) (1) |
| Nov 20, 2024 | 18 | ANSWER to 1 Complaint, by Ascent Pharmaceuticals, Inc..(Hitch, Cortlan) (Entered: 11/20/2024) (25) |
| Nov 5, 2024 | N/A | Pro Hac Vice Attorney Diva Hollis for Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., and Astellas Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:24-cv-00939-JFB-EGT, 1:24-cv-00940-JFB-EGT, 1:24-cv-01068-JFB-EGT, 1:24-cv-01069-JFB-EGT, 1:24-cv-01084-JFB-EGT(cdd) (Entered: 11/05/2024) (0) |
| Nov 5, 2024 | N/A | Pro Hac Vice Attorney James F. Hurst for Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., and Astellas Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:24-cv-00939-JFB-EGT, 1:24-cv-00940-JFB-EGT, 1:24-cv-01068-JFB-EGT, 1:24-cv-01069-JFB-EGT, 1:24-cv-01084-JFB-EGT(mpb) (Entered: 11/05/2024) (0) |
| Oct 30, 2024 | 17 | Pro Hac Vice Fee - Credit Card Payment received for James F. Hurst, Jeanna M. Wacker, Bryan S. Hales, Ashley Ross, and Diva Hollis. ( re 16 MOTION for Pro Hac Vice Appearance of Attorney James F. Hurst, Jeanna M. Wacker, Bryan S. Hales, Ashley Ross, and Diva Hollis )( Payment of $ 250, receipt number ADEDC-4536662).(Silver, Daniel) (Entered: 10/30/2024) (0) |
| Oct 30, 2024 | N/A | SO ORDERED, re (D.I. 16 in 1:24-cv-01084-JFB-EGT, D.I. 16 in 1:24-cv-00939-JFB-EGT, D.I. 16 in 1:24-cv-00940-JFB-EGT, D.I. 11 in 1:24-cv-01068-JFB-EGT & D.I. 11 in 1:24-cv-01069-JFB-EGT) MOTION for Pro Hac Vice Appearance of Attorney James F. Hurst, Jeanna M. Wacker, Bryan S. Hales, Ashley Ross, and Diva Hollis, filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc. ORDERED by Judge Eleanor G. Tennyson on 10/30/2024. (Associated Cases: 1:24-cv-00939-JFB-EGT, 1:24-cv-00940-JFB-EGT, 1:24-cv-01068-JFB-EGT, 1:24-cv-01069-JFB-EGT, 1:24-cv-01084-JFB-EGT) (lah) (Entered: 10/30/2024) (0) |
| Oct 30, 2024 | 16 | MOTION for Pro Hac Vice Appearance of Attorney James F. Hurst, Jeanna M. Wacker, Bryan S. Hales, Ashley Ross, and Diva Hollis - filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Attachments: # 1 Certifications for James F. Hurst, Jeanna M. Wacker, Bryan S. Hales, Ashley Ross, and Diva Hollis)Motions referred to Eleanor G. Tennyson.(Silver, Daniel) (Entered: 10/30/2024) (0) |
| Oct 29, 2024 | N/A | SO ORDERED, re 14 MOTION for Pro Hac Vice Appearance of Attorney Simon D. Roberts, Jason A. Leonard, Vincent Li, and Jayita Guhaniyogi, filed by Astellas Ireland Co., Ltd., Astellas Pharma Inc., Astellas Pharma Global Development, Inc. ORDERED by Judge Eleanor G. Tennyson on 10/29/2024. (lah) (Entered: 10/29/2024) (0) |
| Oct 29, 2024 | 15 | Pro Hac Vice Fee - Credit Card Payment received for Simon D. Roberts, Jason A. Leonard, Vincent Li, and Jayita Guhaniyogi. ( re 14 MOTION for Pro Hac Vice Appearance of Attorney Simon D. Roberts, Jason A. Leonard, Vincent Li, and Jayita Guhaniyogi )( Payment of $ 200, receipt number ADEDC-4535586).(Silver, Daniel) (Entered: 10/29/2024) (0) |
| Oct 29, 2024 | 14 | MOTION for Pro Hac Vice Appearance of Attorney Simon D. Roberts, Jason A. Leonard, Vincent Li, and Jayita Guhaniyogi - filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Attachments: # 1 Certifications for Simon D. Roberts, Jason A. Leonard, Vincent Li, and Jayita Guhaniyogi)Motions referred to Eleanor G. Tennyson.(Silver, Daniel) (Entered: 10/29/2024) (0) |
| Oct 21, 2024 | 13 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Private Limited for MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Dorsney, Kenneth) (Entered: 10/21/2024) (2) |
| Oct 21, 2024 | 12 | ANSWER to 1 Complaint, by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc..(Dorsney, Kenneth) (Entered: 10/21/2024) (30) |
| Oct 18, 2024 | N/A | SO ORDERED granting 11 STIPULATION TO EXTEND TIME for Ascent to Answer, Move or Otherwise Respond to the Complaint to November 20, 2024. (Reset Answer Deadlines: Ascent Pharmaceuticals, Inc. answer due 11/20/2024). ORDERED by Judge Eleanor G. Tennyson on 10/18/2024. (lah) (Entered: 10/18/2024) (0) |
| Oct 18, 2024 | 11 | STIPULATION TO EXTEND TIME for Ascent to Answer, Move or Otherwise Respond to the Complaint to November 20, 2024 - filed by Ascent Pharmaceuticals, Inc.. (Dorsney, Kenneth) (Entered: 10/18/2024) (2) |
| Oct 15, 2024 | 10 | ORAL ORDER - Pursuant to the filing of this case, the Court issues the following order: Magistrate Judge Tennyson shall issue a scheduling order when appropriate. Magistrate Judge Tenyson shall handle all nondispositive matters on all issues, except for Daubert motions, Markman hearings, and pretrial motions in limine. The parties have the right to file an appeal of the magistrate judge's order, and the same shall be decided by the undersigned. The magistrate judge shall likewise handle all discovery matters, scheduling, and pretrial conferences. If the parties believe the magistrate judge has a conflict of interest with this case, the parties shall so notify the Court. IT IS SO ORDERED. Signed by Judge Joseph F. Bataillon on 10/15/24. (AEV) (Entered: 10/15/2024) (0) |
| Oct 2, 2024 | N/A | Case Assigned to Judge Joseph F. Bataillon of the United States District Court for the District of Nebraska, due to related cases. Please include the initials of the Judge (JFB) after the case number on all documents filed. Associated Cases: 1:24-cv-01068-JFB, 1:24-cv-01069-JFB, 1:24-cv-01084-JFB (rjb) (Entered: 10/02/2024) (0) |
| Oct 2, 2024 | 9 | SUMMONS Returned Executed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc..MSN Pharmaceuticals Inc. served on 9/30/2024, answer due 10/21/2024. (Silver, Daniel) (Entered: 10/02/2024) (2) |
| Oct 2, 2024 | 8 | DECLARATION of Service for MSN Laboratories Private Limited by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Attachments: # 1 Exhibit A-B)(Silver, Daniel) (Entered: 10/02/2024) (0) |
| Oct 2, 2024 | 7 | DECLARATION of Service for Ascent Pharmaceuticals, Inc. by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (Attachments: # 1 Exhibit A-B)(Silver, Daniel) (Entered: 10/02/2024) (0) |
| Sep 27, 2024 | 6 | Summons Issued as to Ascent Pharmaceuticals, Inc. on 9/27/2024; MSN Laboratories Private Limited on 9/27/2024; MSN Pharmaceuticals Inc. on 9/27/2024. (Attachments: # 1 Summons Issued, # 2 Summons Issued)(cdd) (Entered: 09/30/2024) (0) |
| Sep 27, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas Pharma Inc., Corporate Parent Astellas B.V. for Astellas Ireland Co., Ltd.; Corporate Parent Astellas Pharma Inc., Corporate Parent Astellas US Holding, Inc. for Astellas Pharma Global Development, Inc. filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.(cdd) (Entered: 09/30/2024) (3) |
| Sep 27, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 12,059,409; 11,707,451; 12,097,189. (cdd) (Entered: 09/30/2024) (1) |
| Sep 27, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 3/22/2023. Date of Expiration of Patent: See Attached. (cdd) (Entered: 09/30/2024) (3) |
| Sep 27, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cdd) (Entered: 09/30/2024) (3) |
| Sep 27, 2024 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Ascent Pharmaceuticals, Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. ( Filing fee $ 405, receipt number ADEDC-4510528.) - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc. (Attachments: # 1 Exhibit A-F, # 2 Civil Cover Sheet)(cdd) (Entered: 09/30/2024) (0) |
